Watson Confirms Lialda Patent Challenge

Watson Pharmaceuticals confirmed that its subsidiary, Watson Laboratories, filed an ANDA with the FDA seeking approval to market Mesalamine delayed-release tablets, 1.2g. Watson’s ANDA product is a generic version of Shire’s Lialda.
The Sacramento Bee